Revumenib

CHEMBL4650827 Phase 4 Aprovado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

630.8 g/mol

LogP

4.3

Phase

4

Revumenib is a potent, selective menin inhibitor that disrupts the interaction between the menin protein and KMT2A (MLL1) fusion oncoproteins, restoring normal differentiation programs in leukemic cells by abrogating aberrant transcriptional activation of HOXA genes and MEIS1. It is approved for relapsed or refractory acute leukemia with KMT2A translocation and is under investigation in NPM1-mutant AML and other menin-dependent malignancies.

Peso Molecular

630,8000 g/mol

LogP

4,30

TPSA

116,00 Å²

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estrutura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CCN(C(=O)c1cc(F)ccc1Oc1cncnc1N1CC2(CCN(C[C@H]3CC[C@H](NS(=O)(=O)CC)CC3)CC2)C1)C(C)C

InChI

InChI=1S/C32H47FN6O4S/c1-5-39(23(3)4)31(40)27-17-25(33)9-12-28(27)43-29-18-34-22-35-30(29)38-20-32(21-38)13-15-37(16-14-32)19-24-7-10-26(11-8-24)36-44(41,42)6-2/h9,12,17-18,22-24,26,36H,5-8,10-11,13-16,19-21H2,1-4H3/t24-,26-

Molecular Formula

C32H47FN6O4S

HBD / HBA

1 / 10

Ligações Rotacionáveis

11

Átomos Pesados

44

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

Revumenib is a potent, selective menin inhibitor that disrupts the interaction between the menin protein and KMT2A (MLL1) fusion oncoproteins, restoring normal differentiation programs in leukemic cells by abrogating aberrant transcriptional activation of HOXA genes and MEIS1. It is approved for relapsed or refractory acute leukemia with KMT2A translocation and is under investigation in NPM1-mutant AML and other menin-dependent malignancies.

Yes, Revumenib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4650827. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 132212657. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Procura informações acessíveis para o paciente?

Revumenib no PillFYI

Estrutura

Dados Rápidos

Fórmula: C32H47FN6O4S
Sinônimos: 1

Links Externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.